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Abstract
The estrogen receptor (ER) pathway and the epidermal growth factor receptor (EGFR) pathway play pivotal roles in
breast cancer progression. Targeted therapies able to intercept ER or signaling downstream to EGFR and its kin,
HER2, are routinely used to treat distinct groups of breast cancer patients. However, patient responses are limited
by resistance to endocrine therapy, which may be due to compensatory HER2/EGFR signaling. This raises the pos-
sibility that simultaneous interception of HER2 and ERmay enhance therapeutic efficacy. To address the question, we
treated breast cancer cells with both fulvestrant (ICI 182780), an ER antagonist with no agonist effects, and lapatinib,
an orally available tyrosine kinase inhibitor specific to EGFR and HER2. Our results indicate that the combination of
drugs is especially effective when applied to HER2-overexpressing, ER-positive cancer cells. Interestingly, fulvestrant
activated the mitogen-activated protein kinase (MAPK) pathway of these cells, but complete inhibition of MAPK sig-
naling was observed on cotreatment with lapatinib. Taken together, our observations reinforce the possibility that the
effectiveness of combining anti-ER and anti-HER2/EGFR drugs may be especially effective on a relatively small sub-
type of HER2-overexpressing, ER-positive tumors of the breast.
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Introduction
Targeted therapies are in common clinical use for the treatment of
breast cancer. Approximately 70% of breast cancers are estrogen re-
ceptor α (ERα)–positive [1,2], and 20% to 25% of mammary tu-
mors present overexpression of HER2 (also called ErbB-2/neu), a
receptor tyrosine kinase related to epidermal growth factor receptor
(EGFR) [3]. Although most ERα-positive mammary tumors initially
respond to therapy with antiestrogens such as tamoxifen, acquired
patient resistance severely limits therapeutic efficacy [4,5]. Several
mechanisms of endocrine resistance have been proposed [6]. They
include deregulation of various components of the ER pathway itself,
alterations in molecules responsible for cell cycle and cell survival,
and the activation of escape pathways that can provide tumors with
alternative proliferative and survival stimuli. Among these, increased
expression or signaling of growth factor receptor pathways has been
associated with both experimental and clinical resistance to endocrine
therapy [7–9].
The ERBB family of receptor tyrosine kinases plays important roles
in the development of resistance to endocrine therapy [10–14]. This
family consists of four members, namely, EGFR, HER2/ERBB2,
HER3/ERBB4, and HER4/ERBB4, which execute multiple functions
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such as cell growth, differentiation, motility, and regulation of apoptosis,
through a complex interplay of homodimerization and heterodimeriza-
tion of the four ERBBmembers [15]. HER2 is the main signal amplifier
of this growth factor receptor family, and it was previously observed to
regulate ERα expression and activity through neuregulins, HER3/
HER4 ligands, which stimulate phosphoinositol 3-kinase signaling to
protein kinase B [16]. In addition, both ErbB members and ERα use
the mitogen-activated protein kinase/extracellular signal-regulated kinase
(ERK) pathway as a major route of cellular activation [17].
Lapatinib (GW 2016) is a potent inhibitor of both the HER2 and
the EGFR tyrosine kinase catalytic functions [18]. It has been shown
that lapatinib cooperates with tamoxifen by inhibiting both cell pro-
liferation and estrogen-dependent gene expression in breast cancer
cells [19]. Moreover, when combined with lapatinib, letrozole, an
aromatase inhibitor, significantly improved progression-free survival
of patients with metastatic breast cancer that coexpresses hormone
receptors and HER2 [20,21]. Fulvestrant (ICI 182780) is a pure anti-
estrogen, a steroidal 7-α-alkylsulphinyl analog of 17β-estradiol, which
is structurally distinct from the nonsteroidal selective ER modulator
tamoxifen [22]. Fulvestrant competitively inhibits binding of estradiol
to the ER, thereby inducing a conformational change within the recep-
tor, different from that of tamoxifen or estradiol [23]. Trastuzumab and
mAb-431 are monoclonal antibodies against the HER2 receptor, of
which trastuzumab is in common clinical use [24] and mAb-431 is a
murine antibody specific to human HER2 [25]. As ERα and growth
factor signaling pathways interact, combining fulvestrant and lapatinib/
anti-HER2 mAbs might present a useful approach for targeting breast
tumors coexpressing ERα and HER2. In this work, we tested whether
the combination of lapatinib and fulvestrant is superior to the respective
single treatments on ERα-positive mammary cell lines with variable
levels of HER2, by analyzing effects on cell growth, cell cycle distribu-
tion, apoptosis, and protein expression levels. The results we present
propose that the drug combination is especially effective when applied
to HER2-overexpressing, ER-positive cancer cells, but it may also affect
cancer cells expressing moderate levels of HER2.
Materials and Methods
Materials
Lapatinib was provided by GlaxoSmithKline (Brentford, UK).
Fulvestrant (ICI 182,780) was supplied by Tocris Bioscience (Tocris
Cookson Ltd, Bristol, UK). Trastuzumab was provided by Genentech,
Inc (South San Francisco, CA). The previously described [25] mono-
clonal antibody to HER2, mAb-431, was produced by Adar Biotech
(Rehovot, Israel). Antibodies against PDK1, p-PDK1, AKT-1, and
p-AKT (Ser473) were purchased from Cell Signaling Technology,
Inc (Boston, MA). Antibodies against ERα, ERK1, and p-ERK1/2
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
The secondary antibodies antirabbit-antibody HRP-linked immu-
noglobulin G was from Cell Signaling Technology, Inc, and the sta-
bilized goat antimouse HRP-conjugated antibody was from Pierce
(Rockford, IL).
Cell Cultures and Proliferation Assays
Cells were grown in Dulbecco modified Eagle medium (Sigma-
Aldrich, Rehovot, Israel). Fetal bovine serum (10%) was added together
with 1% penicillin/streptomycin. BT474, T47D, and MCF-7 cells
were supplied by the European Collection of Cell Cultures (Salisbury,
UK). Before the MTT tests, cells were grown for 24 hours in 96-well
plates at a concentration of 3000 cells per well. In all experiments, we
used phenol red–free medium, containing 1% charcoal-depleted fetal
calf serum (PERBIO Science, Fischer, Germany) and penicillin/strep-
tomycin at a final concentration of 1%. Estrogen was added to a final
concentration of 10 nM. The Sigma M2128 Cell proliferation Kit I
(MTT) was used according to the manufacturer’s instructions. The
XTTCell Proliferation Assay Kit was obtained from Biological Industries
(Beit HaEmek, Israel). The percentage of viable cells was calculated as
follows: ([absorption sample − absorption blank] / [absorption control −
absorption blank]) × 100.
Immunoblot Analyses
Total protein concentration of samples was evaluated by the
BCA protein assay kit (Perbio Science Deutschland GmbH, Bonn,
Germany). A total of 40 μg of protein was separated by 4% to 12%
gradient SDS-PAGE and transferred to poly(vinylidene fluoride) mem-
branes (BIO-RAD, Muenchen, Germany). Blocking was performed
using PBS–Tween-20 (0.1%) with Roti-Block (Roth, Karlsruhe,
Germany) at 4°C for 12 hours. Primary antibodies were incubated
for 2 hours at room temperature. After thorough washing, membranes
were incubated for 90 minutes with peroxidase-conjugated secondary
antibodies. Signals were detected by chemiluminescence using the ECL
detection system (Amersham Pharmacia Biotech, Freiburg, Germany).
Flow Cytometry Analyses
Cells were treated for 48 hours with dimethyl sulfoxide, lapatinib
(0.1 μM), fulvestrant (0.1 μM), or their combination (0.1 μM each).
After collection, cells were washed with saline and fixed with ethanol.
Cells were again washed with saline and treated with solution 1, contain-
ing 100 μg/L RNase, 3.4 mM trisodium citrate, 0.1% Igepal, 1.5 mM
sperminetetrahydrochloride, and 0.5 mM tris(hydroxymethyl)amino-
methane. Subsequently, cells were stained with solution 2 (208 mg/L
propidium iodide, 3.4 mM trisodium citrate, 0.1% Igepal, 1.5 mM
sperminetetrahydrochloride, and 0.5 mM tris-[hydroxymethyl]-
aminomethane) and incubated for 15 minutes at room temperature.
Around 20,000 cells were analyzed using a flow cytometer (FACS
Calibur; BectonDickinson, Heidelberg, Germany). Data were analyzed
using ModFit software (Verity Software House, Topsham, ME) and
confirmed in at least two independent experiments.
Morphogenesis Assays
Eight-well chamber slides (BD Biosciences) were coated using 35 μl
of Matrigel per well. After regular growth in tissue culture dishes, cells
were trypsinized and resuspended in phenol red–free assay medium
supplemented with Matrigel (5%) and serum (5%).
Modeling and Quantification of Drug Synergy
Nonparametric modeling methods were applied to quantify syner-
gism between two drugs. For each viability curve, the data set was
interpolated by a linear piece-wise function. We then calculated (by
means of a numerical integration) this interpolating curve and the hor-
izontal line of 100% viability. These two steps were performed using
Matlab “interp1” and “quad” functions. The resulting area, called
viability area, can quantify the activity of the drug administered. The
larger the calculated area is, the more effective the treatment applied will
be. We assumed that if two drugs have a synergistic effect, the area in
the case of drug combination should be closed by the mean of the single
areas of the two drugs taken alone. In the case where the area resulting
from the combination is larger than this mean, we considered that the
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effect was synergistic. The percentage of synergism between the two
drugs was expressed as the rate of increase of the area of the combina-
tion with respect to the mean of the single areas of the two drugs when
administered alone.
Results
In Vitro Growth-Inhibitory Effects of Lapatinib, Fulvestrant,
and Their Combination on Mammary Tumor Cell Lines
To test the possible interactions between an anti-HER2 drug (lapatinib)
and an anti-ER drug (fulvestrant) on the viability of ER-positive breast
cancer, we used three cell lines that differ in their HER2 expression levels,
namely MCF7 (low level of expression), T47D (medium level of expres-
sion), and BT474 cells, which overexpress HER2. Figure 1A presents an
immunoblot showing the relative expression levels of HER2 and ER in
the three cell lines, which reflect the general reciprocal relations between
HER2 and ER levels. Cells were cultured for 24 hours and were there-
after treated for 72 hours with increasing concentrations of lapatinib
and/or fulvestrant (Figure 1B). The combination of lapatinib and
fulvestrant exerted a superior inhibitory effect on viability of BT474
cells at all drug concentrations we tested. In T47D cells, a superior
effect was observed only with relatively high concentrations of the drug
combination, and in MCF7 cells, we observed superiority of the
combination at low drug concentrations, but at higher concentrations,
Figure 1. Growth-inhibitory effects of lapatinib and fulvestrant on cultures of breast cancer cell lines. (A) BT474, T47D, and MCF7 cells
were grown to semiconfluence. Afterward, cells were harvested and cleared lysates subjected to immunoblot analysis using the indi-
cated antibodies. (B) BT474, T47D, and MCF7 cells were cultured for 24 hours; afterward, they were treated for 72 hours in the presence
of increasing drug concentrations, as indicated. Thereafter, an MTT assay was performed as described in the Materials and Methods
section, and cell viability was presented relative to control, untreated cells. Results are presented as mean and SD (bars) of six wells. The
experiment was performed thrice. (C) BT474 and T47D cells were cultured for 24 hours; afterward, they were treated for 48 hours in the
presence of increasing concentrations of the indicated drugs. Thereafter, an XTT assay was performed, and cell viability was presented
relative to control, untreated cells. Results are presented as relative control, untreated cells. Mean and SD (bars) of six wells are shown.
The experiment was repeated thrice.
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fulvestrant showed a stronger effect than lapatinib. In conclusion, the
drug combination exerted a superior combinatorial effect on ER-positive
breast cancer cells according to the levels of HER2: the combination
was stronger on BT474 cells than in the medium and low expressors
T47D and MCF7 cells, respectively. The latter cells express relatively
high levels of ER and, accordingly, displayed an enhanced sensitivity to
high fulvestrant concentrations than to the combination of drugs. To
address the question whether the improved combinatorial activity of
lapatinib and fulvestrant could be due to the enhanced degradation
of the ER, we probed cell extracts for ERα after 24 hours of treatment
with the drugs. Our preliminary results (data not shown) indicated that
fulvestrant, unlike lapatinib, caused partial degradation of ERα in
T47D and MCF7 cells, but complete disappearance of ERα was noted
after a combined treatment with the drugs. These observations there-
fore raise the possibility that the addition of an anti-HER2 targeting
drug to fulvestrant may decrease ER levels. In addition, we compared
the effects of fulvestrant and tamoxifen on the viability of BT474 and
T47D cells but observed only minor differences (Figure 1C).
To determine whether the observed superior effect of the combi-
nation of lapatinib and fulvestrant on BT474 cells was additive or
synergistic, we quantified the cell viability results and used the non-
parametric method as explained before. After a combinatorial treat-
ment, a strong increase of the viability area could be observed in
BT474 cells, and a smaller increase in comparison to single treatments
could be observed in T47D cells. In MCF7 cells, the area with the high-
est viability was obtained by treating with fulvestrant (Figure 2A). To
calculate whether the observed viability effects of the combinatorial
drug treatments of BT474 and T47D cells were additive or synergistic,
we set the estimated additive effect as a normalization reference (0%).
The enhancement of inhibition of cell viability beyond the additive
effect was 119% for BT474 cells, 21.8% for T47D cells, and 3.2%
for MCF7 cells (Figure 2B). These results indicated a clear synergistic
effect of the combination of lapatinib and fulvestrant when applied on
BT474 cells, along with a mild synergistic effect on T47D cells.
Effects of Lapatinib, Fulvestrant, and Their Combination on
the Cell Cycle Distribution of BT474, T47D, and MCF7 Cells
Ligand-occupied ER is known to promote cell cycle progression
[26]. Hence, in the next step, we tested whether the observed drug-
induced inhibition of cell viability was due to the effects on cell cycle
distribution. BT474, T47D, and MCF7 cells were cultured for
48 hours with lapatinib (100 nM), fulvestrant (100 nM), or with a
combination of both drugs, and the cells were subjected to cell sort-
ing. An increase in the fraction of cells found within the G1 phase and
a concomitant decrease of BT474 cells within the S phase was ob-
served after treatment with fulvestrant or with the drug combination
(Figure 3, upper panel ). In contrast, the cell cycle distribution of
T47D cells was less affected by the drug (Figure 3, middle panel ),
whereas in MCF7 cells, which express high levels of ER, fulvestrant
and its combination with lapatinib exerted the most pronounced
effects (Figure 3, bottom panel; a reduction in the fraction of cells in
the G2 phase plus those from the S phase, from 19.4% of untreated
cells to 5.2% of fulvestrant-treated cells). Interestingly, the effects of
lapatinib on cell cycle distribution were much smaller than the effects
of fulvestrant. In conclusion, the inhibition of ERα signaling in
MCF7 cells, which are estrogen dependent and highly express ER,
showed the most pronounced effect on cell cycle distribution. This is in
accordance with early observations that antiestrogens, such as tamoxifen,
can effectively block estrogen-mediated cell cycle progression [26,27].
Effects of Lapatinib, Fulvestrant, and Their Combination
on Protein Kinase Signaling in Mammary Tumor Cells
Next, we examined the effects of lapatinib and fulvestrant on signal-
ing along the main protein kinase pathways involved in HER2 signal-
ing and endocrine resistance, namely, AKT and PDK1, as well as ERK,
after single and combined treatments with lapatinib and fulvestrant.
BT474 (Figure 4A), T47D (Figure 4A), and MCF7 (Figure 4B) cells
were grown to semiconfluence and treated for 2 hours with relatively high
concentrations of fulvestrant (1 μM), lapatinib (2 μM), or fulvestrant
(1 μM) plus lapatinib (2 μM). Afterwards, cells were harvested and
subjected to immunoblot analysis with the indicated antibodies.
When tested on BT474 cells, lapatinib significantly reduced phos-
phorylation of ERK and AKT, but not PDK1. Nevertheless, fulvestrant
slightly increased phosphorylation of ERK and AKT but weakly de-
creased PDK1 phosphorylation. Interestingly, the combination of
lapatinib and fulvestrant almost erased phosphorylated ERK and
AKT signals (Figure 4A), which may explain the growth-inhibitory
effect of this combination on HER2-overexpressing cells. The levels
of p-PDK1 were also reduced after treatment with the drug combi-
nation. In T47D cells (Figure 4A), lapatinib and the combination of
fulvestrant and lapatinib reduced the levels of phosphorylated ERK
to a similar extent, whereas fulvestrant and fulvestrant plus lapatinib
reduced phosphorylation levels of PDK1 to a similar extent, suggesting
distinct downstream effects of lapatinib and fulvestrant in T47D cells. In
MCF7 cells (Figure 4B), the combination of drugs induced a stronger
Figure 2. The combination of lapatinib and fulvestrant displays dis-
tinct effects on viability of ER-positive breast cancer cells. (A) BT474,
T47D, and MCF7 cells were cultured for 24 hours and afterward
treated with the indicated drugs for 72 hours. Thereafter, an MTT
assay was performed, and cell viability was presented relative to
control, untreated cells. The viability area was calculated from cell
viability assays performed in the presence of increasing concentra-
tions of fulvestrant, lapatinib, or their combination. (B) The relative
increase of a combinatorial treatment of BT474, T47D, and MCF7
cells with lapatinib and fulvestrant (in comparison to additive effects)
was calculated based on the assays presented in Figure 1.
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effect on the reduction of levels of phosphorylated ERK, whereas the
levels of phosphorylated AKT and PDK1were not affected. Interestingly,
p-ERK levels increased under single fulvestrant treatment in BT474
cells (Figure 4A), pointing toward a compensatory ERK signaling when
HER2 is highly expressed. This effect could be completely blocked by
lapatinib. It is notable that BT474 cells exhibited higher sensitivity than
the other two cell lines to the combination of lapatinib and fulvestrant,
and these cells also showed the highest synergistic drug effect on cell
viability (Figure 1A).
Compensatory activation of EGFR and concomitant ERK signal-
ing were previously observed after treatment of mammary cells with
tamoxifen [28]. Although fulvestrant is a complete ER antagonist, in
contrast with the mixed activity of tamoxifen, the observed activation
of ERK in fulvestrant-treated cells may reflect a shared compensatory
mechanism, which is likely mediated by EGFR or HER2 because
lapatinib completely blocked ERK activation in fulvestrant-treated cells.
Effects of Lapatinib, Fulvestrant, and Monoclonal Antibodies
on the Proliferation of BT474 and T47D Cells
To extend the observations made using HER2-overexpressing
BT474 cells and the moderate expressors, T47D, we tested whether
the superior effect of the drug combination would be reflected by a
mode of HER2 inhibition other than lapatinib. Hence, we tested
proliferation of BT474 and T47D cells when treated with fulvestrant
alone, or in combination with lapatinib, trastuzumab, or mAb-431, a
murine anti-HER2 monoclonal antibody [25] (Figure 5). In consis-
tency with our previous results, all combinations we tested were
clearly superior to the respective single drug treatments when applied
to BT474 cells. Likewise, T47D cells displayed much milder combi-
natorial effects, in line with their lower abundance of HER2: the
combinations lapatinib-fulvestrant and trastuzumab-fulvestrant were
more effective than the respective single treatments, whereas the im-
pact of combining mAb-431 with fulvestrant was less effective. Inter-
estingly, the fulvestrant-trastuzumab combination was more effective
than the fulvestrant-lapatinib pair, probably due to the relatively low
concentration of lapatinib (25 nM) used in this experiment. Notably,
at this concentration, lapatinib was ineffective when singly applied,
but it clearly synergized with fulvestrant when the combination was
applied on BT474 cells. In conclusion, these results propose that
blocking HER2 by either a kinase inhibitor or a monoclonal anti-
body can synergize with an ER antagonist, especially when the com-
binations are applied on HER2-overexpressing breast cancer cells.
Figure 3. Effects of lapatinib, fulvestrant, and their combination on
cell cycle distribution of ER-positive breast cancer cells. BT474,
T47D, and MCF7 cells were cultured for 48 hours with lapatinib
(100 nM), fulvestrant (100 nM), or their combination (100 nM each).
Cells were harvested as described in the Materials and Methods
section, and cell cycle assays were performed using 20,000 cells
and a flow cytometer. Data analysis was performed using ModFit.
Results are presented as mean and SD (bars) of three indepen-
dent experiments.
Figure 4. Effects of lapatinib, fulvestrant, and their combination on
intracellular signaling of ER-positive breast cancer cells. Semi-
confluent cultures of BT474 and T47D (A) and MCF7 (B) cells were
treated for 2 hours with fulvestrant (1 μM), lapatinib (2 μM), or
fulvestrant (1 μM) plus lapatinib (2 μM). Afterward, cells were
harvested, and whole lysates were subjected to immunoblot anal-
ysis with antibodies specific to the phosphorylated forms of the
indicated kinases (e.g., p-ERK) or to the respective general forms
(e.g., g-ERK).
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Effects of Lapatinib, Fulvestrant, and Monoclonal Anti-HER2
Antibodies on BT474 Mammospheres
We previously demonstrated that three-dimensional spheroids of
mammary cells grown in extracellular matrix (Matrigel) offer sensitive
readouts when comparing effects of drugs on cell viability [29]. Hence,
to extend the observations made with cellular monolayers, we cultured
BT474 as spheroids embedded in cellular matrix (Figure 6). On day 4,
lapatinib (50 nM), trastuzumab (5 μg/ml), mAb-431 (5 μg/ml), fulves-
trant (250 nM), or their combinations were added to the culture me-
dium. The images of 15-day-old spheroids (Figure 6A) were used to
calculate cross-sectional areas (Figure 6B; on average, 95 spheroids were
used per measurement). As we previously demonstrated, the cross-
sectional area of a spheroid is a reliable parameter of cell viability and
proliferation. Remarkably, all three drug combinations we used, namely,
trastuzumab plus lapatinib, fulvestrant plus lapatinib, and mAb-431
plus lapatinib, exhibited a statistically superior ability to reduce spher-
oid size in comparison with the respective single treatments, which were
quite effective on their own. In line with viability assays performed in
cell monolayers, the combinations of fulvestrant with either lapatinib or
trastuzumab yielded maximal inhibitory effects in this assay. In sum-
mary, our observations indicate that the combination of fulvestrant
and lapatinib is able to strongly reduce viability of ERα-positive,
HER2-overexpressing BT474 breast cancer cells grown either in mono-
layers or in spheroids. This inhibition is attributable to an inhibitory
effect of the drug mixture on two kinase cascades, ERK and AKT. Like
lapatinib, monoclonal antibodies specific to HER2 enhanced the effect
of the ER antagonist, thus confirming the molecular mechanism and
propose ways to translate these observations to clinical applications.
Discussion
Approximately two-thirds of newly diagnosed breast tumors are ER-
positive [1,2], and almost one quarter of all breast cancers overexpress
HER2 [3]. Close to half of the latter group presents ER positivity,
leading to enhanced cell proliferation. Both anti–endocrine- and anti–
HER2-targeted therapies proved their clinical efficacy in the treatment
of ER-positive and HER2-positive breast cancer, respectively. Never-
theless, primary and evolving (secondary) resistance severely limit anti-
endocrine therapy [10,30,31]. Because resistance commonly entails
activation of compensatory signaling pathways, understanding the un-
derlying routes of growth factor signaling, as well as their cross talk and
interfaces with the steroid hormone axis of breast cancer, represents a
prerequisite for the development of new combinatorial therapeutic
strategies able to improve clinical efficacy [6,32].
A recent clinical study examined the question whether the combi-
nation of an antihormonal agent and trastuzumab (without chemo-
therapy) could prove useful as a treatment of HER2/ER-positive
metastatic breast cancer in postmenopausal patients [21]. Trastuzumab
plus anastrozole improved outcomes in the examined subgroup in the
median progression-free survival (4.8 vs 2.4 months). Yet, another re-
cently reported clinical trial [20] examined the question whether the
addition of lapatinib to letrozole in the treatment of postmenopausal
breast cancer patients with HER2- and ER-positive metastatic breast
cancer could provide added efficacy. In this trial, combination therapy
compared with letrozole alone significantly enhanced progression-free
survival (8.2 vs 3.0 months). Thus, there is experimental evidence that
combining anti-HER2 and endocrine treatments is clinically beneficial.
The results of our in vitro studies are in line with these observations as
the maximal combinatorial effect was observed in BT474, representing
HER2-overexpressing, ERα-positive breast cancer cells. Nevertheless,
some effects of the drug combination were also observed with the other
cell lines, although their HER2 levels are lower. Therefore, we assume
that a drug combination strategy may be extended to ER-positive breast
lesions, which express moderate levels of HER2. Notably, a recent clinical
trial reported that a higher dose of fulvestrant (500 vs 250 mg/month)
significantly increased progression-free survival of postmenopausal women
with ER-positive advanced breast cancer, whose conditions progressed
under prior endocrine therapy [33]. In relation to the in vitro results, it
is relevant that higher doses of fulvestrant might also be beneficial in
a combination treatment regimen because maximal antiproliferative
effects of the drug combination were observed at relatively high fulvestrant
doses in all three cell lines we tested.
Acquired resistance to tamoxifen was previously shown to be cor-
related with markedly increased abundance of EGFR and HER2 in
the MCF7 xenograft model [10]. This study concluded that the
EGFR/HER2 compensatory route might mediate tamoxifen resis-
tance in ER-positive breast cancer, despite continued suppression
of ER genomic functions under endocrine therapy. The bidirectional
cross talk between growth factor receptors and hormone receptors
seems responsible for another type of resistance, to lapatinib. A model
system based on the HER2-overexpressing BT474 cells, which became
resistant to lapatinib after chronic treatment, showed derepression of
the transcription factor FOXO3a and consequent activation of ER
signaling in the resistant cells [34]. To directly address the possible
influence of HER2 abundance, our study compared the effects of
Figure 5. Effects of lapatinib, anti-HER2 antibodies, and fulves-
trant, as well as their combinations, on proliferation of BT474
and T47D breast cancer cells. BT474 and T47D cells were cultured
for 24 hours and afterward treated for 48 hours with the indicated
drugs. The following concentrations were used, either alone or in
combinations: fulvestrant (125 nM), lapatinib (25 nM), mAb-431
(2.5 μg/ml), and trastuzumab (2.5 μg/ml). An XTT assay was per-
formed as described in the Materials and Methods section, and
the results are presented as percentage of control untreated cells.
Mean and SD (bars) of triplicates are shown. The experiment was
repeated thrice.
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lapatinib and fulvestrant on ER-positive breast cancer cell lines, which
express HER2 at different levels. The results we obtained indicate that
the best inhibitory action was achieved in BT474 cells, which moderately
express ERα and overexpress HER2. In additional experiments, we were
able to extend this observation to an alternative HER2-blocking strategy,
namely, the combination of fulvestrant with either trastuzumab or mAb-
431 (an inhibitor of HER2 dimerization), in both two-dimensional
and three-dimensional cell culture formats. Combining lapatinib and
fulvestrant also proved some superior efficacy compared with the
single-drug applications in T47D cells, which moderately express
HER2, implying that HER2 can influence cell growth and survival
even before achieving full overexpression. In line with this observation,
our previous experiments showed that targeting HER2 in non–HER2-
overexpressing cell lines led to reduced cell viability and proliferation in
two-dimensional and three-dimensional culture formats [29]. A recent
work defined the EGF-upregulated transcriptional program in MCF7
cells and found it to be correlated with the most highly expressed genes
in HER2-expressing breast cancer [35]. Interestingly, HER2-induced
ERK signaling was previously observed to be important for the cyto-
plasmic localization of ERα, which is involved in the onset of tamoxifen
resistance of HER2-overexpressing cell lines [36]. Our experiments
showed an increase in the phosphorylated levels of ERK in BT474 cells
after treatment with fulvestrant. This effect could be completely
blocked by the combination of lapatinib and fulvestrant, indicating
once again the importance of pathway cross talk and inhibition of
complementary mechanisms.
In summary, we propose a dual combination strategy for the treat-
ment of ER-positive breast tumors that overexpress HER2 but also
for ER-positive breast tumors that express intermediate levels of the
oncoprotein. The strategy comprises mixing of fulvestrant and either
lapatinib or a monoclonal antibody against HER2. Theoretical con-
siderations predict that simultaneous blockade of two major hubs of
signaling networks would be very effective, especially when the in-
hibited hubs generate partly redundant signals [37], because such
networks have not been trained to overcome uncommon perturba-
tions [38]. Our in vitro studies support these notions and also predict
that the combined treatment would delay onset of resistance to ste-
roid hormone blockers. Future studies in vitro and in animals may
improve our understanding as well as determine the exact level of
HER2 abundance needed for synergistic drug interactions, paving
the way for additional clinical trials combining anti-ER and anti-
HER2 drugs.
Figure 6. Effects of lapatinib, trastuzumab, mAb-431, fulvestrant, and their combinations on BT474 spheroids grown in the extracellular
matrix. (A) BT474 cells were seeded in the Matrigel to form spheroids. The following treatments were initiated 4 days later: lapatinib
(50 nM), trastuzumab (5 μg/ml), mAb-431 (5 μg/ml), fulvestrant (250 nM), as well as the indicated drug combinations. The respective
media were refreshed every 4 days. Spheroid images shown were captured on day 15. (B) Images of 15-day-old BT474 spheroids, which
were obtained and treated as in A, were analyzed, and cross-sectional areas were quantified using ImageJ (National Institutes of Health,
Bethesda, MD). On average, 95 spheroids were analyzed after each treatment, and two independent experiments were performed. Each
treatment was compared with the untreated control group using the Mann-Whitney test and SPSS (Armonk, NY). Bonferroni corrections of
calculated P values were used. Asterisks refer to statistically significant differences.
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